Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies
Peiguo Cao, Philippe Merle, Ho Yeong Lim, Ann‐Lii Cheng et al.
Citations
6 citations
Journal
JHEP Reports
Topics
Cancer Immunotherapy and Biomarkers
Field-Weighted Citation Impact (FWCI)
6.27
article
Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies
Peiguo Cao, Philippe Merle, Ho Yeong Lim, Ann‐Lii Cheng, Liangjun Zhu, Masatoshi Kudo, Shukui Qin, Julien Edeline, Yueyin Pan, Richard S. Finn, Mohamed Bouattour, Wei Li, Ping Yang, Ting‐Tsung Chang, Xi Chen, Chen Li, Wei Wang, Jianfeng Li, Kangsheng Gu, Kyung-Hun Lee, Abby B. Siegel
article en
6 citations
Abstract
No abstract available for this paper.
Publication Tag
JHEP ReportsVol. 7(6)
Institutions
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Central South University (CN), University of California, Los Angeles (US), Jilin University (CN), Anhui Medical University (CN), Hôpital Beaujon (FR), Samsung Medical Center (KR), Seoul National University Hospital (KR), Hôpital de la Croix-Rousse (FR), Hospices Civils de Lyon (FR), First People's Hospital of Foshan (CN), Centre Eugène Marquis (FR), Fuzhou General Hospital of Nanjing Military Command (CN), First Hospital of Jilin University (CN), Jiangsu Cancer Hospital (CN), Anhui Provincial Hospital (CN), National Taiwan University Hospital (TW), First Affiliated Hospital of Anhui Medical University (CN), Third Xiangya Hospital (CN), National Cheng Kung University Hospital (TW), Sungkyunkwan University (KR), Kindai University (JP)